•
Patient Reported Outcomes (PROs) are defined as "any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else. The outcome can be measured as the severity of a symptom, sign, or state of a disease, or as a change from a previous measure." 1 
The US Food and Drug Administration (FDA) released a Guidance on the use of PRO measures to support labelling claims, while the European Medicines Agency (EMA) released a reflection paper on the use of health related quality of life measures (HRQL) in response to the FDA guidance. 1,2 Japan's Pharmaceutical and Medical Devices Agency (PMDA) has made no official comment or statement on the use of PRO claims for drug labelling.
In Japan, the Package Insert (PI) information is regulated strictly by the PMDA, but manufacturers may include PRO claims based on their research data in the Interview Form (IF), which contains supplementary information that is provided to pharmacists and contain explanatory material concerning the product.
3
• A previous study on PROs in oncology drugs in Japan revealed no label claims but inclusion in IFs.
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• The purpose of this research was to determine whether drugs that had previously received both US FDA and EMA approval for PRO label claims also had the same PRO claims in Japan. We considered two levels: (1) Although not yet prominent in Japan, PROs are used in drug clinical trials and label claims. There are currently some hurdles that need to be overcome for eventual label claims in Japan, however, manufacturers seem to consider PRO information essential in distinguishing their products.
Conclusion
1. This study only covers 14 drugs that have previously received PRO approval from both the US FDA and EMA. It does not include drugs that have approval from just either one, hence, the number of drugs in Japan that have PRO label claims may actually be higher. However, the aim of this paper was to find commonality across the three governing agencies in terms of PRO approvals. Of the 14 drugs that received PRO Label Claim approval from the US FDA and EMA, only 10 are currently available in Japan. Of these 10 drugs, only 9 used PRO data in clinical trial endpoint positioning and/or label claims, while one drug with an FDA and EMA-approved "symptoms" claim did not have such in its Japan clinical trial.
The positioning of PRO data in clinical trial endpoints varied among the 9 drugs. The PRO endpoints were as follows: two drugs, indicated for epileptic seizure and for benign prostatic hyperplasia, had "symptoms" as a primary endpoint; a drug for rheumatoid arthritis (RA) had "functioning" as its lead secondary endpoint; the remaining six drugs (for pulmonary arterial hypertension (PAH), Crohn's Disease, smoking cessation, Myasthenia Gravis, asthma, and overactive bladder) had HRQOL, symptoms, and functioning as minor secondary endpoints.
